The exciting and sometimes downright crazy giant stem cell ecosystem of legit research and unproven stem cell clinics could use a dose of good news now and then. In today post, I highlight some upbeat news and some interesting recent pubs. Enjoy! From a team led by Hina Chaudhry, MD, Director of Cardiovascular Regenerative Medicine at …
There’s nothing like stem cell good news and interesting publications to perk one up on a Monday. Enjoy. What recent papers have struck you as exciting? Novel stem cell-based cancer approaches (Part 1) It was exciting when Fate Therapeutics got the first induced pluripotent stem cell (IPSC) IND in the U.S. for their IPSC-derived natural killer cell …
Stem cell good news: novel cancer work, new CA bills, Alzheimer’s, & more pubs Read More »
What new papers and news in the stem cell sphere caught your eye? Here are some recent items that seem notable to me. Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells. This paper reports cellular reprogramming to insulin-producing cells in mice. They reprogrammed α-cells with Pdx1 and MafA proteins. ‘Mitophagy inhibits amyloid-β and tau pathology and reverses …
Recent stem cell pubs & news: reprogramming, chromatin, single-cell, Astellas, & more Read More »
In the past month or two there has been a steady stream of good news in the stem cell and regenerative medicine world. Here are three examples starting with Fate Therapeutics. Fate Therapeutics Fate Therapeutics announced the first US IND for an induced pluripotent stem cell (IPSC)-related product. Its cleared product, FT500, is an off-the-shelf …
Stem cell & regenerative medicine good news including Fate Therapeutics Read More »
Magenta Therapeutics is a biotech company with a portfolio including stem cell products. Their most well known investigational drug product is an expanded umbilical cord stem cell product called MGTA-456, an “ex-Novartis” product. Magenta just released new trial data on MGTA-456, which I see as a case of good news-bad news, and investors seem to …
Magenta Therapeutics Good News-Bad News Trial Data Read More »
Stem cells are always in the news so what’s up in the last week or two? CIRM News The dialogue over CIRM’s future is picking up a bit of steam. The San Francisco Chronicle did an in-depth piece on CIRM some weeks back and then opined that they didn’t feel supportive of another round of …
News bites: CIRM, anti-MSCs, & human eggs from stem cells Read More »
Sometimes it seems like a bunch of stuff in one area, like with CRISPR this week, happens all of a sudden in science. A bunch of fairly high-profile gene editing pubs came out. They generated a lot of news reports. Other news in this arena popped up too, all within a few days. In vivo …
CRISPR update: lots of new pubs, news, & maybe a patent finale Read More »
Sometimes we could all use a jolt of good news and cool science. Those of us in the stem cell field probably get tired at times of all the bad-ish, even if important news (like this from Michael Hiltzik of the LA Times) out there surrounding certain unproven stem cell offerings and also clinics that …
Some stem cell good news, stuff for debate, & cool pubs Read More »
Stem cell news is always burbling up, sometimes right there in front of us on the web and other times via networks of people. Astellas news. Some may remember there used to be this pioneering stem cell biotech called ACT, which then became Ocata, and finally was acquired by the big company Astellas. One of …
Stem cell news bites: Astellas trial, cystic fibrosis claim, a few cool papers Read More »
The year of 2018 has already been a wild one for stem cell news. There are many developments on a variety of fronts. Here are some of the most notable news bites of the last month or so. RMATs RMAT Wave. The FDA continues its warp-speed issuance of Regenerative Medicine Advanced Therapy (RMAT) designations with …
Stem cell news July 2018: RMATs, RTT, MiMedx mess, clinic family ties & more Read More »